TNF-α inhibitors have been shown to reduce the prevalence of diabetes and metabolic syndrome in patients with psoriasis through clinical studies, but are associated with an increased risk of weight gain, the paradox of which requires further investigation [35,36]. This evidence concerns the gene TNF and metabolic syndrome.